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Background: Thrombolytic therapy is still used for patients presenting with ST-elevation myocardial infarction. The safety and efficacy of bivalirudin 
(BIV) for primary percutaneous coronary intervention (PCI) in these patients has not been established. This study aimed to compare the safety of BIV 
vs unfractionated heparin (UFH) in patients undergoing primary PCI following initial management with thrombolytic therapy.
Methods: A series of 104 consecutive patients treated with primary PCI, who received full dose thrombolytic therapy within 6 hours prior to 
the intervention, was identified and retrospectively analyzed. The use of intraprocedural UFH and BIV was compared for in-hospital bleeding and 
ischemic events.
Results: This series includes 47 patients (45%) treated with BIV and 57 patients (55%) treated with UFH. The baseline characteristics were similar 
in both groups. Patients on BIV more frequently received low-molecular weight heparin and were more frequently pre-loaded with clopidogrel. 
Intraprocedural glycoprotein IIb/IIIa inhibitors were used only in UFH patients. Incidence of TIMI major bleeding was similar. Other bleeding events 
and ischemic endpoints were more frequent in patients treated with UFH but results did not reach statistical significance. (Table)
Conclusions: During primary PCI, use of BIV after initial management with thrombolytics appears as safe as UFH. A randomized trial addressing 
safety and outcomes of BIV after lytic therapy is warranted.
Comparison of Bivalirudin and UFH. Basic demographics, adjunctive therapy and in-hospital outcomes.
Bivalirudin (%) Heparin (%) p value
Age (years) 56.6 ±14.7 55.4 ±10.8 0.636
Male 83.0 86.0 0.647
Low-molecular weight heparin 42.6 21.4 0.021
Intra-procedural IIb/IIIa Inhibitor 0.0 31.6 <.001
Pre-load with clopidogrel 56.5 28.1 0.003
TIMI major bleed 4.3 3.5 1.0
TIMI minor bleed 2.1 7.0 0.375
CVA/TIA 0.0 3.5 0.5
Death 2.1 5.3 0.625
